New NIH centers to validate Alzheimer’s targets

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new research centers tasked with validating new drug targets.

NIH’s National Institute on Aging (NIA) launched the centers, dubbed Alzheimer Centers for the Discovery of New Medicines, on Tuesday, which will receive over $73 million combined over five years...